Trial · NCT02055157
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Summary of Adverse Events During Initial 6-Month Period | Up to Month 6 ± 7 Days | Safety Analysis Population includes all subjects who received at least one dose of study treatment and were used for safety analysis in the initial 6-month period and entire study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Overall Summary of Adverse Events During Entire Study Period | Up to Month 25 ± 7 Days | Safety Analysis Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Annualized Growth Velocity (AGV) During Initial 6-Month | At 6 month (Day 183) | Efficacy Analysis Population includes all subjects who received at least one dose of study treatment and who had post treatment data for any efficacy endpoint in the corresponding period were included in the Efficacy Analysis and Extension Efficacy Analysis population. | cm/year | MEAN |
| SECONDARY | Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 3 and 4 | At month 24 | Efficacy Analysis Population | cm/year | MEAN |
| SECONDARY | Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 1 and 2 Switchers | At month 24 | Efficacy Analysis Population | cm/year | MEAN |
| SECONDARY | Change From Baseline in Height Z-Scores Using Centers for Disease Control and Prevention (CDC) Reference Standard During Initial 6-Months | At month 6 (Day 183) | Efficacy Analysis Population | z score | MEAN |
| SECONDARY | Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 3 and 4 | At month 24 | Efficacy Analysis Population | z score | MEAN |
| SECONDARY | Change From Baseline in Height Z-Scores Using CDC Reference Standard During Entire Study Period - Cohort 1 and 2 Switchers | At month 24 | Efficacy Analysis Population | z score | MEAN |
| SECONDARY | Change From Baseline in Upper to Lower Body Ratios During Initial 6-Months | At month 6 (Day 183) | Efficacy Analysis Population | Ratio | MEAN |
| SECONDARY | Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 3 and 4 | At month 24 | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Arm Length to Lower Arm (Forearm) Length Ratio During Initial 6-Months | At month 6 (Day 183) | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 3 and 4 | At month 24 | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper to Lower Body Ratios During Entire Study Period - Cohort 1 and 2 Switchers | At month 24 | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Arm to Lower Arm Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers | At month 24 | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Initial 6-months | At month 6 (Day 183) | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 3 and 4 | At month 24 | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Leg Length (Thigh) to Knee to Heel Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers | At month 24 | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Initial 6-months | At month 6 (Day 183) | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 3 and 4 | At month 24 | Efficacy Analysis Population | ratio | MEAN |
| SECONDARY | Change From Baseline in Upper Leg Length (Thigh) to Tibial Length Ratio During Entire Study Period - Cohort 1 and 2 Switchers | At month 24 | Efficacy Analysis Population | ratio | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02055157/outcomes